Vitazi.ai Announces Partnership with Eye Associates of New Mexico to Advance AI-Powered Retinal Screening

SANTA FE, N.M., Feb. 12, 2025 /PRNewswire/ -- Vitazi.ai, Inc., a key leader in Oculomics, is pleased to announce an agreement with Eye Associates of New Mexico, the largest ophthalmology organization in the state. Eye Associates sees between 1400 and 1500 patients daily at its 11 clinics throughout the state. In addition to these 11 clinics, Eye Associates has three surgery centers and 10 optical shops. This collaboration marks a significant step in harnessing artificial intelligence to revolutionize retinal diagnostics and early disease detection.

Oculomics, the study of the retina using AI, has emerged as a groundbreaking field with the potential to detect systemic diseases?including cardiovascular disease, neurodegenerative disorders, and diabetes?years before clinical symptoms appear. By leveraging this partnership, Vitazi.ai Chief Technology Officer, Dr. Jeffrey Wigdahl, PhD, and his team of retinal researchers at Vitazi.ai will research and develop new Oculomics tools on OculoInsightstm, Vitazi.ai's revolutionary AI-powered retinal diagnostic and early disease detection platform, designed to empower retinal specialists and healthcare providers with advanced screening capabilities.

"This agreement with Eye Associates of New Mexico brings us closer to a future where AI-powered retinal imaging can provide early and more accurate diagnoses, improving patient outcomes on a global scale," said Dr. Jeremy Stueven, MD, MBA, Founder and CEO of Vitazi.ai, Inc. "By building a platform of AI models of the retina, we are laying the foundation for an accessible, AI-driven healthcare revolution that will transform disease screening and preventive medicine."

OculoInsightstm, Vitazi.ai's AI-powered web-based platform, aims to democratize access to cutting-edge diagnostic tools. Oculomics, as a field, will soon empower physicians to use retinal biomarkers to detect numerous diseases?such as Alzheimer's, hypertension, and metabolic disorders?sometimes before they manifest clinically. While Vitazi.ai can not detect all of these diseases today, the robust dataset provided through this partnership will enable Vitazi.ai to research and develop additional Oculomics tools with the goal of earlier interventions and better patient care.

As a leader in Oculomics, Vitazi.ai continues to push the boundaries of AI-driven healthcare innovation, working toward a world where AI retinal screening becomes a routine and powerful tool in early disease detection.

For more information, visit www.vitazi.ai.

Media Contact:
Katheryn Sosa, MD
[email protected]
1-833-4-VITAZI
Vitazi.ai, Inc.

SOURCE Vitazi.ai